| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00176306 | Obesity|Critical Illness | Drug: Levofloxacin 750 mg IV | University of Kentucky|Ortho-McNeil Pharmaceutical | Phase 4 | 2005-01-01 | 2012-09-12 |
| NCT02018081 | Intensive Care Unit Syndrome|Community-acquired Pneumonia | Drug: Levofloxacin | University Hospital, Toulouse | Phase 4 | 2012-03-01 | 2015-03-04 |
| NCT01055145 | TB | Drug: levofloxacin, moxifloxacin | Seoul National University Hospital | Phase 3 | 2010-03-01 | 2012-11-22 |
| NCT00645437 | Renal Diseases | Drug: Levofloxacin | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2004-10-01 | 2011-06-06 |
| NCT01371656 | Acute Leukemias of Ambiguous Lineage|Bacterial Infection|Diarrhea|Fungal Infection|Musculoskeletal Complications|Neutropenia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies | Drug: levofloxacin | Children's Oncology Group|National Cancer Institute (NCI) | Phase 3 | 2011-06-01 | 2017-02-13 |
| NCT01761201 | Latent Tuberculosis Infection|Infection in Solid Organ Transplant Recipients | Drug: Levofloxacin|Drug: Isoniazid | Fundacin Pblica Andaluza para la gestin de la Investigacin en Sevilla|Spanish Network for Research in Infectious Diseases | Phase 3 | 2012-01-01 | 2014-08-05 |
| NCT01575899 | Helicobacter Pylori Infection | Drug: Levofloxacin-Amox/clav.|Drug: Clarithromycin-Amoxicillin | Buddhist Tzu Chi General Hospital | Phase 4 | 2007-12-01 | 2012-07-28 |
| NCT00764582 | Corneal Transplantation | Drug: 1.5% levofloxacin ophthalmic solution|Drug: 0.5% moxifloxacin ophthalmic solution | Santen Inc.|Vistakon Pharmaceuticals | Phase 4 | 2008-09-01 | 2009-08-24 |
| NCT02884713 | GASTRITIS | Drug: Levofloxacin|Drug: Doxycycline|Drug: Esomeprazole | King Faisal Specialist Hospital & Research Center | | 2013-06-01 | 2016-08-25 |
| NCT01168713 | Community-Acquired Bacterial Pneumonia | Drug: Levofloxacin|Drug: CEM-101 | Cempra Inc | Phase 2 | 2010-08-01 | 2017-03-01 |
| NCT01537055 | Eradication Rate for Helicobacter | Drug: levofloxacin-based sequential therapy|Drug: levofloxacin-based triple therapy for 10 days | National Taiwan University Hospital|E-DA Hospital | Phase 4 | 2012-02-01 | 2015-01-30 |
| NCT01710488 | COPD Exacerbation | Drug: Levofloxacin 1 tablet 500 mg once a day|Drug: Prulifloxacin 1 tablet 600 mg once a day | Fadoi Foundation, Italy | Phase 4 | 2009-05-01 | 2017-01-11 |
| NCT01529476 | Pneumonia | Drug: Levofloxacin|Drug: Nemonoxacin | TaiGen Biotechnology Co., Ltd.|Qualitix Clinical Research Co., Ltd.|Parexel|PPD | Phase 3 | 2011-04-01 | 2013-06-17 |
| NCT01978938 | Complicated Urinary Tract Infections (cUTI) | Drug: Eravacycline|Drug: Levofloxacin | Tetraphase Pharmaceuticals, Inc. | Phase 3 | 2013-12-01 | 2016-05-24 |
| NCT01524302 | Pneumonia, Bacterial|Community-acquired | Drug: Ceftaroline|Drug: Levofloxacin | Gary E. Stein, Pharm.D.|Forest Laboratories|Michigan State University | Phase 4 | 2012-02-01 | 2016-03-14 |
| NCT01467297 | COPD Exacerbation | Drug: ceftidoren|Drug: levofloxacin | University of Milan | Phase 4 | 2012-01-01 | 2012-06-02 |
| NCT00035347 | Community-Acquired Pneumonia (CAP) | Drug: IV azithromycin|Drug: ceftriaxone|Drug: oral azithromycin|Drug: IV levofloxacin|Drug: oral levofloxacin | Pfizer | Phase 4 | 2001-01-01 | 2017-03-07 |
| NCT00376376 | Healthy Volunteers | Drug: levofloxacin at 250, 500, 750, and 1000 mg doses | Michigan State University|PriCara, Unit of Ortho-McNeil, Inc. | | 2006-09-01 | 2008-11-25 |
| NCT02699658 | Healthy Volunteers | Drug: Levofloxacin | Prince of Songkla University | Phase 2 | 2013-10-01 | 2016-03-03 |
| NCT01345929 | Complicated Urinary Tract Infection|Pyelonephritis | Drug: CXA-201|Drug: Levofloxacin | Cubist Pharmaceuticals LLC | Phase 3 | 2011-06-01 | 2016-01-06 |
| NCT00565123 | Bacterial Conjunctivitis | Drug: 0.5% levofloxacin eye drops|Drug: 0.5% levofloxacin eye drops | Laser Microsurgery Centre, Poland|Katedra I Klinika Okulistyki II Wydz. Lek. AM w Warszawie,|University Hospital No 1 Wroclaw|MedSource Polska | Phase 2|Phase 3 | 2004-09-01 | 2007-11-28 |
| NCT03038321 | Non-Muscle-invasive Bladder Cancer (NMIBC)|Bacillus Calmette-Guerin (BCG) Cystitis|Intra-vesical Instillation | Drug: sofenacin|Drug: Tavanic|Drug: Xefo | Mansoura University | Phase 4 | 2017-02-01 | 2017-03-20 |
| NCT00906048 | Infection | Drug: Levofloxacin (HR355) and Rifampicin Therapy | Sanofi | Phase 3 | 2009-04-01 | 2011-02-04 |
| NCT00495339 | Tuberculosis, Pulmonary | Drug: Levofloxacin | Sanofi | Phase 4 | 2007-06-01 | 2009-03-03 |
| NCT00453349 | Pelvic Inflammatory Disease | Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Levofloxacin & Metronidazole | Bayer | Phase 3 | 2007-01-01 | 2014-09-02 |
